Etoposide

Generic Name
Etoposide
Brand Names
Etopophos, Toposar, Vepesid
Drug Type
Small Molecule
Chemical Formula
C29H32O13
CAS Number
33419-42-0
Unique Ingredient Identifier
6PLQ3CP4P3
Background

A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to ce...

Indication

For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions
Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer
Associated Therapies
-
Clinical Trials
Related News

CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients

First Posted Date
2024-02-16
Last Posted Date
2024-02-16
Lead Sponsor
Princess Maxima Center for Pediatric Oncology
Target Recruit Count
60
Registration Number
NCT06262438
Locations
🇳🇱

Princess Máxima Center for pediatric oncology, Utrecht, Netherlands

Neoadjuvant Therapy With Toripalimab and JS004 Combined With Etoposide and Platinum Chemotherapy for Limited-stage Small Cell Lung Cancer : A Phase 2 Trial

First Posted Date
2024-02-13
Last Posted Date
2024-05-29
Lead Sponsor
Shanghai Pulmonary Hospital, Shanghai, China
Target Recruit Count
30
Registration Number
NCT06256237
Locations
🇨🇳

Shanghai Pulmonary Hospital, Shanghai, China

Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma

First Posted Date
2024-02-08
Last Posted Date
2024-07-23
Lead Sponsor
OHSU Knight Cancer Institute
Target Recruit Count
40
Registration Number
NCT06249191
Locations
🇺🇸

OHSU Knight Cancer Institute, Portland, Oregon, United States

A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma

First Posted Date
2024-01-30
Last Posted Date
2024-12-10
Lead Sponsor
Regeneron Pharmaceuticals
Target Recruit Count
216
Registration Number
NCT06230224
Locations
🇨🇳

Chang Gung Memorial Hospital Kaohsiung, Kaohsiung City, Taiwan

🇹🇷

VM Medical Park Mersin Hospital, Mezitli, Mersin, Turkey

🇦🇺

Princess Alexandra Hospital, Woolloongabba, Queensland, Australia

and more 54 locations

Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML

First Posted Date
2024-01-24
Last Posted Date
2024-08-22
Lead Sponsor
Children's Hospital of Soochow University
Target Recruit Count
500
Registration Number
NCT06221683
Locations
🇨🇳

The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China

🇨🇳

XiangYa Hospital Central South University, Changsha, Hunan, China

🇨🇳

Children's Hospital of Soochow University, Suzhou, Jiangsu, China

and more 10 locations

Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC

First Posted Date
2024-01-22
Last Posted Date
2024-05-13
Lead Sponsor
Sichuan University
Target Recruit Count
45
Registration Number
NCT06217757
Locations
🇨🇳

West China Hospital of Sichuan University, Chengdu, Si Chuan, China

A Phase Ⅱ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC

First Posted Date
2023-12-20
Last Posted Date
2023-12-20
Lead Sponsor
Nanfang Hospital, Southern Medical University
Target Recruit Count
62
Registration Number
NCT06177925
Locations
🇨🇳

Nanfang Hospital, Southern Medical University, Guangzhou, China

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

First Posted Date
2023-12-15
Last Posted Date
2024-12-18
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
478
Registration Number
NCT06172296
Locations
🇺🇸

Blank Children's Hospital, Des Moines, Iowa, United States

🇺🇸

Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States

🇺🇸

Children's Hospital of Alabama, Birmingham, Alabama, United States

and more 115 locations

Ruxolitinib With De-Intensified HLH-94 for the Treatment of Hemophagocytic Lymphohistiocytosis (HLH)

First Posted Date
2023-12-07
Last Posted Date
2024-10-15
Lead Sponsor
Aaron Logan, MD
Target Recruit Count
36
Registration Number
NCT06160791
Locations
🇺🇸

University of California, San Francisco, San Francisco, California, United States

Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma

First Posted Date
2023-11-21
Last Posted Date
2024-01-03
Lead Sponsor
Wuhan Union Hospital, China
Target Recruit Count
54
Registration Number
NCT06140966
Locations
🇨🇳

Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy